Clinical Trial Update: Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A) [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of a GlaxoSmithKline HPV vaccine (GSK1674330A) in healthy young adult women is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 1 | Status: COMPLETED